Renaissance Technologies LLC Cuts Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Renaissance Technologies LLC lowered its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 3.8% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,114,125 shares of the biopharmaceutical company’s stock after selling 161,500 shares during the quarter. Renaissance Technologies LLC owned about 7.06% of Vanda Pharmaceuticals worth $23,245,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Profit Investment Management LLC boosted its stake in Vanda Pharmaceuticals by 159.3% during the second quarter. Profit Investment Management LLC now owns 571,324 shares of the biopharmaceutical company’s stock valued at $3,228,000 after buying an additional 351,000 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Vanda Pharmaceuticals by 17.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,013,807 shares of the biopharmaceutical company’s stock valued at $11,379,000 after acquiring an additional 292,172 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new position in shares of Vanda Pharmaceuticals in the first quarter valued at $1,158,000. Monaco Asset Management SAM bought a new stake in Vanda Pharmaceuticals in the second quarter worth $1,090,000. Finally, GSA Capital Partners LLP raised its stake in Vanda Pharmaceuticals by 39.8% during the fourth quarter. GSA Capital Partners LLP now owns 567,756 shares of the biopharmaceutical company’s stock valued at $2,396,000 after purchasing an additional 161,737 shares in the last quarter. Institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Stock Down 0.9 %

NASDAQ VNDA opened at $4.61 on Friday. Vanda Pharmaceuticals Inc. has a 52 week low of $3.30 and a 52 week high of $6.75. The firm has a market capitalization of $268.29 million, a price-to-earnings ratio of -57.63 and a beta of 0.77. The company has a fifty day moving average of $5.42 and a two-hundred day moving average of $5.11.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) EPS for the quarter. The firm had revenue of $50.47 million for the quarter. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. Equities research analysts anticipate that Vanda Pharmaceuticals Inc. will post -0.49 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a research note on Saturday, September 14th. They issued a “hold” rating for the company. Cantor Fitzgerald boosted their price objective on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.